Ibogaine Treatment: Addiction Risks, Safety & Alternatives

Medications such as methadone, buprenorphine, and naltrexone are commonly prescribed to treat opioid use disorder. These medications help reduce cravings, ease withdrawal symptoms, and support long-term recovery when combined with counseling and behavioral therapies.

Recent approaches to opioid addiction treatment include extended-release buprenorphine injections and digital therapeutics that support recovery. Research is also exploring psychedelic-assisted therapies, though these remain experimental and are not FDA-approved.

The time it takes for opioid receptors to return to normal function varies. For some people, this can take several weeks to months after stopping opioid use. Healing depends on factors like the type of opioid used, duration of use, and individual brain chemistry.

The FDA has approved lofexidine to manage opioid withdrawal symptoms. Unlike methadone or buprenorphine, it is not an opioid but helps reduce symptoms such as anxiety, sweating, and agitation during detox.

Hallucinogens like LSD, psilocybin, and ibogaine can cause visual and auditory distortions, changes in thought patterns, altered sense of time, and intense emotional shifts. Some individuals may also experience fear or paranoia, known as a “bad trip.”

Hallucinations may involve seeing, hearing, or feeling things that are not real. They can create confusion, anxiety, and impaired judgment, which is why medical supervision is recommended when substances that cause hallucinations are used.

Common symptoms include dilated pupils, rapid mood swings, distorted perceptions, and unusual body movements. In some cases, individuals may struggle to differentiate between reality and hallucination.

Psychedelics affect serotonin receptors, particularly 5-HT2A, altering brain connectivity and perception. This can result in profound changes in consciousness, sensory experiences, and emotional processing.

Iboga root bark has been traditionally used in West African spiritual ceremonies. In modern contexts, ibogaine extracted from the bark has been studied for its potential to reduce opioid withdrawal symptoms, though it remains risky and not legally approved in the U.S.

In many African traditions, ibogaine is simply referred to as iboga, derived from the Tabernanthe iboga shrub. It has cultural and ritual significance, particularly in Gabon’s Bwiti religion.

The Tabernanthe iboga plant is known for its psychoactive properties. Its root bark contains ibogaine, a powerful hallucinogen that induces altered states of consciousness and has been explored for addiction treatment.

People describe iboga root bark as having an extremely bitter, earthy taste. It is generally unpleasant, which can make it difficult to consume in traditional or experimental contexts.

It is used, outside approved medicine, as an attempt to treat opioid addiction. Ibogaine is a hallucinogenic drug made from the root bark of the Tabernanthe iboga plant from West Africa: a stimulant in low doses, strongly psychedelic in higher ones. Some believe it reduces opiate withdrawal symptoms and cravings, and the page is careful here, noting most of that evidence comes from animal studies while ibogaine-related deaths have been reported in humans. From 1990 to 2008 at least 19 deaths were linked to it, and MAPS puts the death rate as high as 1 in 300.

No. Ibogaine is a Schedule I drug in the United States, meaning no accepted medical use, and the FDA has not approved it to treat any substance use disorder. Clinical trials ended after funding stopped and a patient died during treatment. Ibogaine treatments are only available outside the country, and some people travel abroad for them hoping to avoid painful withdrawal. The page flags the risk in doing so: many ibogaine treatment centers do not have trained medical staff.